Video
[URL="https://www.youtube.com/watch?v=7Q1pqUc ... e=youtu.be"][U]Video[/U][/URL]
ECTRIMS - MS Congres
-
Marsei
How People with Multiple Sclerosis Use Social Media
How People with Multiple Sclerosis Use Social Media
How People with Multiple Sclerosis Use [URL="https://www.msconnection.org/Blog/Octob ... ocial-Medi"][U]Social Media[/U][/URL] - Julie Stachowiak (MS patient en arts)
[QUOTE]Bottom Line: What I was trying to convey in my talk was to calm the fears of neurologists about social media and the Internet and how people with MS use them. I think that some neuros picture us excitedly Googling “cure for multiple sclerosis” and simply trusting what we find by trying something that could be potentially harmful. While this has (and does) happen, most of us just want to understand this disease better and know that we are not alone.
We, people with MS, want to be listened to and communicated with. I made the strong recommendation that neurologists join the conversation, demonstrating their interest in what we have to say and giving them a chance to express themselves outside of the all-too-short office visits that are part of our lives. In turn, I promised that we would be nice to them in social media (at least most of the time).[/QUOTE]
How People with Multiple Sclerosis Use [URL="https://www.msconnection.org/Blog/Octob ... ocial-Medi"][U]Social Media[/U][/URL] - Julie Stachowiak (MS patient en arts)
[QUOTE]Bottom Line: What I was trying to convey in my talk was to calm the fears of neurologists about social media and the Internet and how people with MS use them. I think that some neuros picture us excitedly Googling “cure for multiple sclerosis” and simply trusting what we find by trying something that could be potentially harmful. While this has (and does) happen, most of us just want to understand this disease better and know that we are not alone.
We, people with MS, want to be listened to and communicated with. I made the strong recommendation that neurologists join the conversation, demonstrating their interest in what we have to say and giving them a chance to express themselves outside of the all-too-short office visits that are part of our lives. In turn, I promised that we would be nice to them in social media (at least most of the time).[/QUOTE]
-
Leonard
Dank je wel Marsei. Dit is heel nuttig om te zien wat er zo al gebeurd.
Maar mijn vraag is: zie jij verandering? een nieuwe trend? een nieuwe wind? een nieuwe focus? bijv. door meer te kijken naar onderliggende mechanismen, of door meer te kijken naar progressieve MS.
Ik denk dat een verandering van de kijk of van de hele benadering heel belangrijk is. Zo lang ECTRIMS door blijft gaan op de oude weg hoeven we van die kant niet veel te verwachten.
Bij MS behandeling zijn altijd symptomen behandeld; protocols zijn ontworpen "om het immuunsysteem te onderdrukken of moduleren". Maar de werkelijke oorzaken zijn nooit behandeld; MS heeft een protocol nodig dat oorzaken behandelt. Een grondige diepgaande analyse van de ziekte mechanismen is daar voor nodig.
Ik denk dat het concept MS UNRAVELLED posting 10 augustus een heel eind komt in de goede richting. Jammer dat ik zo weinig daarvan terug zie op ECTRIMS.
[url]http://www.thisisms.com/forum/general-d ... 8-720.html[/url]
Maar mijn vraag is: zie jij verandering? een nieuwe trend? een nieuwe wind? een nieuwe focus? bijv. door meer te kijken naar onderliggende mechanismen, of door meer te kijken naar progressieve MS.
Ik denk dat een verandering van de kijk of van de hele benadering heel belangrijk is. Zo lang ECTRIMS door blijft gaan op de oude weg hoeven we van die kant niet veel te verwachten.
Bij MS behandeling zijn altijd symptomen behandeld; protocols zijn ontworpen "om het immuunsysteem te onderdrukken of moduleren". Maar de werkelijke oorzaken zijn nooit behandeld; MS heeft een protocol nodig dat oorzaken behandelt. Een grondige diepgaande analyse van de ziekte mechanismen is daar voor nodig.
Ik denk dat het concept MS UNRAVELLED posting 10 augustus een heel eind komt in de goede richting. Jammer dat ik zo weinig daarvan terug zie op ECTRIMS.
[url]http://www.thisisms.com/forum/general-d ... 8-720.html[/url]
-
neuron
Brain Health Time matters in multiple sclerosis
Brain Health Time matters in multiple sclerosis
De avond voorafgaand aan ECTRIMS (het mocht blijkbaar niet plaatsvinden op ECTRIMS) was er een symposium van 60 minuten met 5 sprekers over [B]Brain Health Time matters in multiple sclerosis[/B].
Hersenen (het brein) van MS patienten krimpen 7x sneller, dan de hersenen van mensen zonder MS (met alle gevolgen voor cognitie etc). Om de krimp tegen te gaan moeten patiënten met MS, in overleg, op tijd en optimaal worden behandeld.
De wens is om zoveel mogelijk patiënten met MS in een database onder te brengen om de effecten van behandeling efficient te kunnen meten en op basis van die gegevens de behandeling te kunnen kiezen die het best bij de patient past.
zie verder
[url]www.msbrainhealth.org[/url]
.
De avond voorafgaand aan ECTRIMS (het mocht blijkbaar niet plaatsvinden op ECTRIMS) was er een symposium van 60 minuten met 5 sprekers over [B]Brain Health Time matters in multiple sclerosis[/B].
Hersenen (het brein) van MS patienten krimpen 7x sneller, dan de hersenen van mensen zonder MS (met alle gevolgen voor cognitie etc). Om de krimp tegen te gaan moeten patiënten met MS, in overleg, op tijd en optimaal worden behandeld.
De wens is om zoveel mogelijk patiënten met MS in een database onder te brengen om de effecten van behandeling efficient te kunnen meten en op basis van die gegevens de behandeling te kunnen kiezen die het best bij de patient past.
zie verder
[url]www.msbrainhealth.org[/url]
.
-
Marsei
Smoking Cessation Slows Brain Volume Loss in Multiple Sclerosis
Smoking Cessation Slows Brain Volume Loss in Multiple Sclerosis
[URL="http://www.neurologyadvisor.com/ectrims ... le/443832/"][U]Smoking Cessation[/U][/URL] Slows Brain Volume Loss in Multiple Sclerosis
[QUOTE]Smoking cessation appears to decelerate loss of brain volume in multiple sclerosis (MS), and may have an effect on long-term clinical outcomes, data presented in a poster session at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress in Barcelona indicate.
In previous research, Ramanujam et al found that for each additional year of smoking after MS diagnosis, conversion to secondary-progressive MS was accelerated by 4.7%. In this study, Navid Seraji-Bozoergzad, MD, assistant professor of neurology at Wayne State University School of Medicine, and colleagues studied the effect of smoking cessation on brain volume in patients with MS.[/QUOTE]
[URL="http://www.neurologyadvisor.com/ectrims ... le/443832/"][U]Smoking Cessation[/U][/URL] Slows Brain Volume Loss in Multiple Sclerosis
[QUOTE]Smoking cessation appears to decelerate loss of brain volume in multiple sclerosis (MS), and may have an effect on long-term clinical outcomes, data presented in a poster session at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress in Barcelona indicate.
In previous research, Ramanujam et al found that for each additional year of smoking after MS diagnosis, conversion to secondary-progressive MS was accelerated by 4.7%. In this study, Navid Seraji-Bozoergzad, MD, assistant professor of neurology at Wayne State University School of Medicine, and colleagues studied the effect of smoking cessation on brain volume in patients with MS.[/QUOTE]
-
Marsei
Karen Lee: Update from ECTRIMS 2015: Day 2
Karen Lee: Update from ECTRIMS 2015: Day 2
[URL="http://drkarenlee.ca/ectrims-2015-day-2/#more-1217"][U]Update from ECTRIMS 2015: Day 2[/U][/URL]
[QUOTE][B]Safety Concerns and Risk Management
[/B]
Dr. Per Sorensen (Danish Multiple Sclerosis Center, Copenhagen, Denmark) gave the state of the union about safety concerns and risk management of MS therapies, emphasizing that treatment with disease modifying therapies (DMTs) should be tailored to each individual to minimize the risk of serious side effects from treatment as much as possible.
Dr. Christoph Heesen (Institute of Neuroimmunology and MS Research, Hamburg, Germany) talked about how establishing a shared decision process between people living with MS and their clinicians, including proper communication and managing perceptions, has an enormous impact on how people living with MS perceive and tolerate risk of serious side effects with their treatments.
Dr. Ilya Kister (New York University School of Medicine, New York, NY) compared relapse rates and disability progression in people living with MS who discontinued their DMTs (DMT stoppers) since their condition was stable to those who continued on therapy (DMT stayers). The team found that DMT stoppers had an increased risk of disability progression, although unexpectedly, they tended to also have a decreased risk of relapse compared to DMT stayers.
A team led by Dr. Jodi Haartsen (Box Hill Hospital, Melbourne, Australia) established and studied the effectiveness of a multi-drug safety module to track treatment safety outcomes, particularly low white blood cell counts in response to treatment. The study showed that this module can be an effective tool that allows clinicians to identify patients who are at a higher risk for serious side effects.
[B]Genetics and the Environment[/B]
A Swedish population-based case control study led by Dr. Lars Alfredsson (Institute of Environmental Medicine, Stockholm, Sweden) investigated the impact of exposure to organic solvents (such as certain paints, printing inks, agricultural products, etc.) and smoking on MS risk in genetically susceptible individuals. The study found that subjects exposed to smoking and organic solvents carrying those genetic risk factors had a relatively higher risk of developing MS.
Drs. Philip De Jager (Brigham & Women’s Hospital, Boston, MA) and Stephen Sawcer (University of Cambridge, Cambridge UK) discussed in vivid detail some of the cutting-edge genetic data mining techniques their teams have used to map out genes that determine susceptibility to MS and figure out which ones work together. This important research allows them to identify common points that could be targeted for future MS prevention strategies.
MS Society of Canada-funded research Dr. Helen Tremlett (University of British Columbia, Vancouver, BC) used the rich dataset from the Nurse’s Health Study to examine the link between sun exposure and MS over the life course, including timing of exposure and potential for sun avoidance. The results of the study confirmed the growing consensus that low exposure to ultraviolet-B radiation over the life course is a risk factor for MS; importantly, she found that people living with MS later in life in particular tended to avoid the sun, which could impact their overall vitamin D status and health.
[B]Hot Topics 2: MS Care 3.0[/B]
This session put the spotlight on personalized therapies and new tools that empower people living with MS to take greater ownership over their condition
Dr. Alessandra Solari (Fondazione Istituto Neurologico C. Besta, Milan, Italy) discussed some of the pros and cons of patient decision aids (PDAs), tools that allow people living with MS and their health care team to work together to make health care decisions based on both clinical evidence and individual values and needs.
Dr. Mathias Mäurer (Caritas Krankenhaus Bad Mergentheim gGmbH, Bad Mergentheim, Germany) discussed the results from a randomized controlled trial examining internet-based interventions (including online consultations, web-based consultations and online therapeutic software) on physical activity, quality of life and fatigue in people living with MS. While physical activity and fitness improved, adhering to the program in the long term proved to be a challenge, prompting the need to refine web-based interventions further.
An online fatigue management program for people living with MS was presented by Dr. Jana Poettgen (University Medical Centre Hamburg Eppendorf, Hamburg, Germany), including results from a randomized controlled trial that tested how such a program can reduce fatigue in people living with MS. The trial showed that this fully automated, web-based program was effective in significantly reducing fatigue as well as showing potential for improving anxiety and cognitive function, offering hope for accessible and low-cost alternatives to cognitive behavioural therapy for people living with MS.[/QUOTE]
[URL="http://drkarenlee.ca/ectrims-2015-day-2/#more-1217"][U]Update from ECTRIMS 2015: Day 2[/U][/URL]
[QUOTE][B]Safety Concerns and Risk Management
[/B]
Dr. Per Sorensen (Danish Multiple Sclerosis Center, Copenhagen, Denmark) gave the state of the union about safety concerns and risk management of MS therapies, emphasizing that treatment with disease modifying therapies (DMTs) should be tailored to each individual to minimize the risk of serious side effects from treatment as much as possible.
Dr. Christoph Heesen (Institute of Neuroimmunology and MS Research, Hamburg, Germany) talked about how establishing a shared decision process between people living with MS and their clinicians, including proper communication and managing perceptions, has an enormous impact on how people living with MS perceive and tolerate risk of serious side effects with their treatments.
Dr. Ilya Kister (New York University School of Medicine, New York, NY) compared relapse rates and disability progression in people living with MS who discontinued their DMTs (DMT stoppers) since their condition was stable to those who continued on therapy (DMT stayers). The team found that DMT stoppers had an increased risk of disability progression, although unexpectedly, they tended to also have a decreased risk of relapse compared to DMT stayers.
A team led by Dr. Jodi Haartsen (Box Hill Hospital, Melbourne, Australia) established and studied the effectiveness of a multi-drug safety module to track treatment safety outcomes, particularly low white blood cell counts in response to treatment. The study showed that this module can be an effective tool that allows clinicians to identify patients who are at a higher risk for serious side effects.
[B]Genetics and the Environment[/B]
A Swedish population-based case control study led by Dr. Lars Alfredsson (Institute of Environmental Medicine, Stockholm, Sweden) investigated the impact of exposure to organic solvents (such as certain paints, printing inks, agricultural products, etc.) and smoking on MS risk in genetically susceptible individuals. The study found that subjects exposed to smoking and organic solvents carrying those genetic risk factors had a relatively higher risk of developing MS.
Drs. Philip De Jager (Brigham & Women’s Hospital, Boston, MA) and Stephen Sawcer (University of Cambridge, Cambridge UK) discussed in vivid detail some of the cutting-edge genetic data mining techniques their teams have used to map out genes that determine susceptibility to MS and figure out which ones work together. This important research allows them to identify common points that could be targeted for future MS prevention strategies.
MS Society of Canada-funded research Dr. Helen Tremlett (University of British Columbia, Vancouver, BC) used the rich dataset from the Nurse’s Health Study to examine the link between sun exposure and MS over the life course, including timing of exposure and potential for sun avoidance. The results of the study confirmed the growing consensus that low exposure to ultraviolet-B radiation over the life course is a risk factor for MS; importantly, she found that people living with MS later in life in particular tended to avoid the sun, which could impact their overall vitamin D status and health.
[B]Hot Topics 2: MS Care 3.0[/B]
This session put the spotlight on personalized therapies and new tools that empower people living with MS to take greater ownership over their condition
Dr. Alessandra Solari (Fondazione Istituto Neurologico C. Besta, Milan, Italy) discussed some of the pros and cons of patient decision aids (PDAs), tools that allow people living with MS and their health care team to work together to make health care decisions based on both clinical evidence and individual values and needs.
Dr. Mathias Mäurer (Caritas Krankenhaus Bad Mergentheim gGmbH, Bad Mergentheim, Germany) discussed the results from a randomized controlled trial examining internet-based interventions (including online consultations, web-based consultations and online therapeutic software) on physical activity, quality of life and fatigue in people living with MS. While physical activity and fitness improved, adhering to the program in the long term proved to be a challenge, prompting the need to refine web-based interventions further.
An online fatigue management program for people living with MS was presented by Dr. Jana Poettgen (University Medical Centre Hamburg Eppendorf, Hamburg, Germany), including results from a randomized controlled trial that tested how such a program can reduce fatigue in people living with MS. The trial showed that this fully automated, web-based program was effective in significantly reducing fatigue as well as showing potential for improving anxiety and cognitive function, offering hope for accessible and low-cost alternatives to cognitive behavioural therapy for people living with MS.[/QUOTE]
-
Marsei
Nervous System Repair – Multiple Strategies in the Pipeline
Nervous System Repair – Multiple Strategies in the Pipeline
[URL="http://www.msconnection.org/Blog/Octobe ... ies-in-the"][U]Nervous System Repair[/U][/URL] – Multiple Strategies in the Pipeline
[QUOTE]Nervous system repair is getting a lot of attention this week in Barcelona at ECTRIMS, the European Committee for Treatment and Research in MS, where 9,000 experts in MS have gathered to share research ideas and results. [/QUOTE]
[QUOTE]Prof. Dennis Bourdette and his team (Oregon Health and Science University) sped up myelin repair in mice using an experimental drug called sobetirome. This agent is a thyroid-like hormone that mimics its biological effects and is already in clinical trials for lowering cholesterol. We know that the thyroid hormone boosts the capabilities of myelin-making cells, but is not a viable therapeutic option for people with MS, due to adverse effects on heart, bone, and muscle. Sorbetirome may work effectively without these side effects; the National MS Society is funding this team to explore this option in MS models. Since it is already in clinical trials for another indication, demonstrating safety and effectiveness may take less time usual. (Abstract P583)
Dr. Bernard Mueller and colleagues (AbbVie Inc.) reported their findings on the experimental therapy ABT-555, which is an antibody to a signaling molecule in the nervous system. When ABT-555 was administered to mice with an MS-like disease, the mice recovered from disease, and experienced both myelin repair and nerve fiber regeneration within spinal cord lesions. The company notes some exciting findings as a result of an early study of this experimental antibody that is underway in healthy volunteers and in people with MS. (Abstract P582)
Some strategies involve improving the “micro” environment in the brain to enable repair, rather than administering a specific therapy. Prof. V. Wee Yong’s team (University of Calgary) is studying microglia, which are brain cells that mimic immune cells known as macrophages. These cells can be either damaging or repairing, depending on the cell subset involved. This group is attempting different strategies to promote the type that does repair. They report that an exercise activity can boost the repair-friendly environment in mouse models of myelin damage. (Abstract 201) Understanding what leads to repair can help to identify treatment candidates that may be already in existence.
Just last week there was an announcement about New York University scientists who uncovered a new approach to stimulating the body’s own resident stem cells to repair myelin. They found that by blocking a molecule present in specific stem cells, they were able to stimulate myelin repair and some recovery in mice with an MS-like disease. In the process, they uncovered a new pathway for stimulating myelin repair and are now working to refine the approach to develop a therapy that may be used to repair myelin in people with MS in the future.[/QUOTE]
[URL="http://www.msconnection.org/Blog/Octobe ... ies-in-the"][U]Nervous System Repair[/U][/URL] – Multiple Strategies in the Pipeline
[QUOTE]Nervous system repair is getting a lot of attention this week in Barcelona at ECTRIMS, the European Committee for Treatment and Research in MS, where 9,000 experts in MS have gathered to share research ideas and results. [/QUOTE]
[QUOTE]Prof. Dennis Bourdette and his team (Oregon Health and Science University) sped up myelin repair in mice using an experimental drug called sobetirome. This agent is a thyroid-like hormone that mimics its biological effects and is already in clinical trials for lowering cholesterol. We know that the thyroid hormone boosts the capabilities of myelin-making cells, but is not a viable therapeutic option for people with MS, due to adverse effects on heart, bone, and muscle. Sorbetirome may work effectively without these side effects; the National MS Society is funding this team to explore this option in MS models. Since it is already in clinical trials for another indication, demonstrating safety and effectiveness may take less time usual. (Abstract P583)
Dr. Bernard Mueller and colleagues (AbbVie Inc.) reported their findings on the experimental therapy ABT-555, which is an antibody to a signaling molecule in the nervous system. When ABT-555 was administered to mice with an MS-like disease, the mice recovered from disease, and experienced both myelin repair and nerve fiber regeneration within spinal cord lesions. The company notes some exciting findings as a result of an early study of this experimental antibody that is underway in healthy volunteers and in people with MS. (Abstract P582)
Some strategies involve improving the “micro” environment in the brain to enable repair, rather than administering a specific therapy. Prof. V. Wee Yong’s team (University of Calgary) is studying microglia, which are brain cells that mimic immune cells known as macrophages. These cells can be either damaging or repairing, depending on the cell subset involved. This group is attempting different strategies to promote the type that does repair. They report that an exercise activity can boost the repair-friendly environment in mouse models of myelin damage. (Abstract 201) Understanding what leads to repair can help to identify treatment candidates that may be already in existence.
Just last week there was an announcement about New York University scientists who uncovered a new approach to stimulating the body’s own resident stem cells to repair myelin. They found that by blocking a molecule present in specific stem cells, they were able to stimulate myelin repair and some recovery in mice with an MS-like disease. In the process, they uncovered a new pathway for stimulating myelin repair and are now working to refine the approach to develop a therapy that may be used to repair myelin in people with MS in the future.[/QUOTE]
-
Marsei
More Data on Daclizumab in MS: DECIDE Published
More Data on Daclizumab in MS: DECIDE Published
More Data on [URL="http://www.medscape.com/viewarticle/852362"][U]Daclizumab[/U][/URL] in MS: DECIDE Published
[QUOTE]The phase 3 DECIDE trial, showing favorable results with the investigational drug daclizumab (Biogen) in multiple sclerosis (MS), has been published in the October 8 issue of The New England Journal of Medicine (NEJM).
The results, which show a reduced relapse rate and a lower number of new lesions on MRI with the new agent vs interferon β-1a, were first reported last year at the MS Boston 2014 meeting.
The 3-month confirmed disability progression (the main disability endpoint) was not significantly improved with daclizumab, but secondary analyses did suggest that 6-month confirmed disability progression was reduced.
In addition, a new analysis from the DECIDE trial presented today at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2015 conference here showed that more patients receiving daclizumab had no evidence of disease activity (NEDA) at 2 years.[/QUOTE]
[QUOTE]The drug, which is given by subcutaneous injection once a month, is awaiting approval for MS in the United States and Europe. It is a humanized monoclonal antibody that binds to CD25 (part of the interleukin-2 receptor) and so modulates interleukin-2 signaling, which is implicated in the pathogenesis of MS.
Professor Kappos added that the positioning of daclizumab will depend on the adverse effects — mainly skin reactions, which can be serious. "The efficacy is better than most first-line treatments. We don't yet know how the regulatory authorities will recommend its use," he said.[/QUOTE]
More Data on [URL="http://www.medscape.com/viewarticle/852362"][U]Daclizumab[/U][/URL] in MS: DECIDE Published
[QUOTE]The phase 3 DECIDE trial, showing favorable results with the investigational drug daclizumab (Biogen) in multiple sclerosis (MS), has been published in the October 8 issue of The New England Journal of Medicine (NEJM).
The results, which show a reduced relapse rate and a lower number of new lesions on MRI with the new agent vs interferon β-1a, were first reported last year at the MS Boston 2014 meeting.
The 3-month confirmed disability progression (the main disability endpoint) was not significantly improved with daclizumab, but secondary analyses did suggest that 6-month confirmed disability progression was reduced.
In addition, a new analysis from the DECIDE trial presented today at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2015 conference here showed that more patients receiving daclizumab had no evidence of disease activity (NEDA) at 2 years.[/QUOTE]
[QUOTE]The drug, which is given by subcutaneous injection once a month, is awaiting approval for MS in the United States and Europe. It is a humanized monoclonal antibody that binds to CD25 (part of the interleukin-2 receptor) and so modulates interleukin-2 signaling, which is implicated in the pathogenesis of MS.
Professor Kappos added that the positioning of daclizumab will depend on the adverse effects — mainly skin reactions, which can be serious. "The efficacy is better than most first-line treatments. We don't yet know how the regulatory authorities will recommend its use," he said.[/QUOTE]
-
Leonard
[QUOTE=neuron;1027343]De avond voorafgaand aan ECTRIMS (het mocht blijkbaar niet plaatsvinden op ECTRIMS) was er een symposium van 60 minuten met 5 sprekers over [B]Brain Health Time matters in multiple sclerosis[/B].
Hersenen (het brein) van MS patienten krimpen 7x sneller, dan de hersenen van mensen zonder MS (met alle gevolgen voor cognitie etc). Om de krimp tegen te gaan moeten patiënten met MS, in overleg, op tijd en optimaal worden behandeld.
De wens is om zoveel mogelijk patiënten met MS in een database onder te brengen om de effecten van behandeling efficient te kunnen meten en op basis van die gegevens de behandeling te kunnen kiezen die het best bij de patient past.
zie verder
[url]www.msbrainhealth.org[/url]
.[/QUOTE]
er zijn meer meetings in de marge van ECTRIMS, waaronder multidisciplinaire meetings met veel -logen rond 1 tafel.
op 1 van die meetings zal mijn thesis MS UNRAVELLED ook aan de orde komen. ;)
ook daarna zijn er meetings waar mijn thesis aan de orde komt.
langzaam, heel langzaam, wordt het monopolie van ECTRIMS ondergraven. dat is goed.
Hersenen (het brein) van MS patienten krimpen 7x sneller, dan de hersenen van mensen zonder MS (met alle gevolgen voor cognitie etc). Om de krimp tegen te gaan moeten patiënten met MS, in overleg, op tijd en optimaal worden behandeld.
De wens is om zoveel mogelijk patiënten met MS in een database onder te brengen om de effecten van behandeling efficient te kunnen meten en op basis van die gegevens de behandeling te kunnen kiezen die het best bij de patient past.
zie verder
[url]www.msbrainhealth.org[/url]
.[/QUOTE]
er zijn meer meetings in de marge van ECTRIMS, waaronder multidisciplinaire meetings met veel -logen rond 1 tafel.
op 1 van die meetings zal mijn thesis MS UNRAVELLED ook aan de orde komen. ;)
ook daarna zijn er meetings waar mijn thesis aan de orde komt.
langzaam, heel langzaam, wordt het monopolie van ECTRIMS ondergraven. dat is goed.
-
neuron
[QUOTE=Leonard;1027436]er zijn meer meetings in de marge van ECTRIMS, waaronder multidisciplinaire meetings met veel -logen rond 1 tafel.
op 1 van die meetings zal mijn thesis MS UNRAVELLED ook aan de orde komen. ;)
ook daarna zijn er meetings waar mijn thesis aan de orde komt.
langzaam, heel langzaam, wordt het monopolie van ECTRIMS ondergraven. dat is goed.[/QUOTE]
Leo, doe niet zo geheimzinnig!
Welke meetings en wanneer.
.
op 1 van die meetings zal mijn thesis MS UNRAVELLED ook aan de orde komen. ;)
ook daarna zijn er meetings waar mijn thesis aan de orde komt.
langzaam, heel langzaam, wordt het monopolie van ECTRIMS ondergraven. dat is goed.[/QUOTE]
Leo, doe niet zo geheimzinnig!
Welke meetings en wanneer.
.